Review

adavosertib plasma concentration determination (LabCorp)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

LabCorp adavosertib plasma concentration determination
Adavosertib Plasma Concentration Determination, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/adavosertib+concentration+determination/pm37394627-62-3-10?v=LabCorp
Average 90 stars, based on 1 article reviews

adavosertib plasma concentration determination - by Bioz Stars, 2026-08

90/100 stars

Images

Image Search Results

a Study design and b patient disposition flow chart. This manuscript focuses on pharmacokinetic data from part A of NCT03333824; part B of NCT03333824 is an investigation of the effect of adavosertib on the QT interval, results of which are reported separately. *Informed consent received; † A number of patients enrolled more than once; there were 49 unique enrollments; ‡ Study treatment refers to treatment with either cocktail or adavosertib; § One each as a result of death (pancreatic cancer), study termination by the sponsor, and withdrawal by the patient. bid twice daily

Journal: Cancer Chemotherapy and Pharmacology

Article Title: Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

doi: 10.1007/s00280-023-04554-3

Figure Lengend Snippet: a Study design and b patient disposition flow chart. This manuscript focuses on pharmacokinetic data from part A of NCT03333824; part B of NCT03333824 is an investigation of the effect of adavosertib on the QT interval, results of which are reported separately. *Informed consent received; † A number of patients enrolled more than once; there were 49 unique enrollments; ‡ Study treatment refers to treatment with either cocktail or adavosertib; § One each as a result of death (pancreatic cancer), study termination by the sponsor, and withdrawal by the patient. bid twice daily

Article Snippet: The concentration of adavosertib in human plasma was determined by Labcorp Bioanalytical Laboratories using the same validated method described previously [ ].

Techniques:

Pharmacokinetic parameter estimates for substrates of CYP1A2 (caffeine), CYP2C19 (omeprazole), and CYP3A (midazolam) and their metabolites (paraxanthine, 5-HO, and 1ʹ-HM, respectively) in the presence and absence of adavosertib 225 mg bid (pharmacokinetic analysis set)

Journal: Cancer Chemotherapy and Pharmacology

Article Title: Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

doi: 10.1007/s00280-023-04554-3

Figure Lengend Snippet: Pharmacokinetic parameter estimates for substrates of CYP1A2 (caffeine), CYP2C19 (omeprazole), and CYP3A (midazolam) and their metabolites (paraxanthine, 5-HO, and 1ʹ-HM, respectively) in the presence and absence of adavosertib 225 mg bid (pharmacokinetic analysis set)

Article Snippet: The concentration of adavosertib in human plasma was determined by Labcorp Bioanalytical Laboratories using the same validated method described previously [ ].

Techniques:

Individual and geometric mean AUC 0–t and C max of a caffeine, b omeprazole, and c midazolam alone versus each cocktail drug plus adavosertib, and d individual and geometric mean of adavosertib plus cocktail (part A) versus adavosertib alone (part B). *Individual patient and geometric mean AUC 0–t and C max in the presence and absence of adavosertib 225 mg bid for caffeine ( n = 25), omeprazole ( n = 27), and midazolam ( n = 23); † Adavosertib + cocktail: caffeine (200 mg tablet), omeprazole (20 mg capsule), and midazolam (1 mL of 2 mg/mL syrup formulation) on day 3 and adavosertib 225 mg (3 × 75 mg capsules) on day 3 (part A). Adavosertib: adavosertib 225 mg (3 × 75 mg capsules) bid on days 1 and 2 and once on day 3 (part B/pharmacodynamic study). AUC 0–12 area under the plasma concentration–time curve from time zero to 12 h, AUC 0–t area under the plasma concentration–time curve from time zero to time of the last quantifiable concentration, C max maximum plasma drug concentration

Journal: Cancer Chemotherapy and Pharmacology

Article Title: Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

doi: 10.1007/s00280-023-04554-3

Figure Lengend Snippet: Individual and geometric mean AUC 0–t and C max of a caffeine, b omeprazole, and c midazolam alone versus each cocktail drug plus adavosertib, and d individual and geometric mean of adavosertib plus cocktail (part A) versus adavosertib alone (part B). *Individual patient and geometric mean AUC 0–t and C max in the presence and absence of adavosertib 225 mg bid for caffeine ( n = 25), omeprazole ( n = 27), and midazolam ( n = 23); † Adavosertib + cocktail: caffeine (200 mg tablet), omeprazole (20 mg capsule), and midazolam (1 mL of 2 mg/mL syrup formulation) on day 3 and adavosertib 225 mg (3 × 75 mg capsules) on day 3 (part A). Adavosertib: adavosertib 225 mg (3 × 75 mg capsules) bid on days 1 and 2 and once on day 3 (part B/pharmacodynamic study). AUC 0–12 area under the plasma concentration–time curve from time zero to 12 h, AUC 0–t area under the plasma concentration–time curve from time zero to time of the last quantifiable concentration, C max maximum plasma drug concentration

Article Snippet: The concentration of adavosertib in human plasma was determined by Labcorp Bioanalytical Laboratories using the same validated method described previously [ ].

Techniques: Formulation, Capsules, Clinical Proteomics, Concentration Assay

Geometric mean (± SD) plasma concentration of a caffeine, b omeprazole, and c midazolam ± adavosertib versus time. Exponential of (mean of log concentration ± SD of log concentration). Probe cocktail: caffeine (200 mg tablet), omeprazole (20 mg capsule), and midazolam (1 mL of 2 mg/mL syrup formulation) on day − 8. Adavosertib + cocktail: cocktail and adavosertib 225 mg (3 × 75 mg capsules) on day 3. SD standard deviation

Journal: Cancer Chemotherapy and Pharmacology

Article Title: Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

doi: 10.1007/s00280-023-04554-3

Figure Lengend Snippet: Geometric mean (± SD) plasma concentration of a caffeine, b omeprazole, and c midazolam ± adavosertib versus time. Exponential of (mean of log concentration ± SD of log concentration). Probe cocktail: caffeine (200 mg tablet), omeprazole (20 mg capsule), and midazolam (1 mL of 2 mg/mL syrup formulation) on day − 8. Adavosertib + cocktail: cocktail and adavosertib 225 mg (3 × 75 mg capsules) on day 3. SD standard deviation

Article Snippet: The concentration of adavosertib in human plasma was determined by Labcorp Bioanalytical Laboratories using the same validated method described previously [ ].

Techniques: Clinical Proteomics, Concentration Assay, Formulation, Capsules, Standard Deviation

Summary of pharmacokinetic parameters of adavosertib following co-administration of cocktail (pharmacokinetic analysis set)

Journal: Cancer Chemotherapy and Pharmacology

Article Title: Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

doi: 10.1007/s00280-023-04554-3

Figure Lengend Snippet: Summary of pharmacokinetic parameters of adavosertib following co-administration of cocktail (pharmacokinetic analysis set)

Article Snippet: The concentration of adavosertib in human plasma was determined by Labcorp Bioanalytical Laboratories using the same validated method described previously [ ].

Techniques:

Review

Structured Review

Images

Similar Products

Image Search Results